Table 3.
Case reports of cefiderocol for multidrug-resistant PA-CNSI.
| Study | Age (y) | Gender | Country | Comorbidity | Pathogen | Regimen | Duration | CSF culture conversion | ADR | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Stevenson et al. (101) | 41 | F | UK | Cerebral hemorrhage | DTR-PA | CFD 1 g, ivgtt, q8h + CMS 5MIU, ivgtt, q12h CFD 1.5 g, ivgtt, q8h + CMS 6 MIU, ivgtt, q12h + CMS 0.125 MIU, ITH, qd | 12 d | Yes | None | Death (non-infectious) |
| Marcelo et al. (102) | 63 | M | Spain | Meningioma | DTR-PA | CFD 2 g, ivgtt, q8h + CMS 4.5 MIU, ivgtt, q12h | 32 d | Yes | None | Cured |
| Luque-Paz et al. (103) | 71 | NA | France | Craniopharyngioma | DTR-PA | CFD 2 g, ivgtt, q8h + CMS 10 mg, IVT, qd + AMK 30 mg, IVT, qd | 15 d | No | None | Death |
| Sollima et al. (104) | 60 | M | Italy | Subarachnoid hemorrhage | MDR-PA | CFD 2 g, ivgtt, q8h + TBM*+ CFX* | 22 d | Yes | None | Death (non-infectious) |
| Sollima et al. (104) | NA | M | Italy | Lung transplant | MDR-PA | CFD 2 g, ivgtt, q8h + FOF* | 3 mon | Yes | None | Cured |
| Sollima et al. (104) | 55 | F | Italy | Hydrocephalus | DTR-PA | CFD 2 g, ivgtt, q8h + FOF* | NA | Yes | None | Cured |
| Sollima et al. (104) | 74 | M | Italy | Meningioma | XDR-PA | CFD* | 21 d | Yes | None | Cured |
DTR-PA, Pseudomonas aeruginosa with difficult-to-treat resistance; XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; CFD, cefiderocol; q8h, every 8 h; q12h, every 12 h; qd, once daily; CMS, colistimethate sodium; IVT, intraventricular; ITH, intrathecal; AMK, amikacin; MDR-PA, multidrug-resistant Pseudomonas aeruginosa; TBM, tobramycin; CFX, ciprofloxacin; FOF, fosfomycin; *, unspecified dosage; NA, not available.